Global Immuno-oncology Drugs Market 2023 by Company, Regions, Type and Application, Forecast to 2029
Page: 123
Published Date: 08 Sep 2023
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Immuno-oncology Drugs market size was valued at USD 18010 million in 2022 and is forecast to a readjusted size of USD 50980 million by 2029 with a CAGR of 16.0% during review period.
Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Immuno-oncology Drugs industry chain, the market status of Hospitals (Immune Checkpoint Inhibitors, Immune System Modulators), Clinics (Immune Checkpoint Inhibitors, Immune System Modulators), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Immuno-oncology Drugs.
Regionally, the report analyzes the Immuno-oncology Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Immuno-oncology Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Immuno-oncology Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Immuno-oncology Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Immune Checkpoint Inhibitors, Immune System Modulators).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Immuno-oncology Drugs market.
Regional Analysis: The report involves examining the Immuno-oncology Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Immuno-oncology Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Immuno-oncology Drugs:
Company Analysis: Report covers individual Immuno-oncology Drugs players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Immuno-oncology Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Clinics).
Technology Analysis: Report covers specific technologies relevant to Immuno-oncology Drugs. It assesses the current state, advancements, and potential future developments in Immuno-oncology Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Immuno-oncology Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Immuno-oncology Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
Market segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Market segment by players, this report covers
Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Dendreon Corporation
Agilent Technologies Inc.
Agenus Inc.
Enzo Biochem, Inc.
Lonza Group
Bio-Rad Laboratories, Inc.
Avantor, Inc.
Spring Bank Pharmaceuticals, Inc.
Ferring Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Immuno-oncology Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Immuno-oncology Drugs, with revenue, gross margin and global market share of Immuno-oncology Drugs from 2018 to 2023.
Chapter 3, the Immuno-oncology Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Immuno-oncology Drugs market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Immuno-oncology Drugs.
Chapter 13, to describe Immuno-oncology Drugs research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Immuno-oncology Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Immuno-oncology Drugs by Type
1.3.1 Overview: Global Immuno-oncology Drugs Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Immuno-oncology Drugs Consumption Value Market Share by Type in 2022
1.3.3 Immune Checkpoint Inhibitors
1.3.4 Immune System Modulators
1.3.5 Cancer Vaccines
1.3.6 Oncolytic Virus
1.3.7 Others
1.4 Global Immuno-oncology Drugs Market by Application
1.4.1 Overview: Global Immuno-oncology Drugs Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Ambulatory Surgical Centers
1.5 Global Immuno-oncology Drugs Market Size & Forecast
1.6 Global Immuno-oncology Drugs Market Size and Forecast by Region
1.6.1 Global Immuno-oncology Drugs Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Immuno-oncology Drugs Market Size by Region, (2018-2029)
1.6.3 North America Immuno-oncology Drugs Market Size and Prospect (2018-2029)
1.6.4 Europe Immuno-oncology Drugs Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Immuno-oncology Drugs Market Size and Prospect (2018-2029)
1.6.6 South America Immuno-oncology Drugs Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Immuno-oncology Drugs Market Size and Prospect (2018-2029)
2.1 Amgen, Inc
2.1.1 Amgen, Inc Details
2.1.2 Amgen, Inc Major Business
2.1.3 Amgen, Inc Immuno-oncology Drugs Product and Solutions
2.1.4 Amgen, Inc Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Amgen, Inc Recent Developments and Future Plans
2.2 AstraZeneca, Plc
2.2.1 AstraZeneca, Plc Details
2.2.2 AstraZeneca, Plc Major Business
2.2.3 AstraZeneca, Plc Immuno-oncology Drugs Product and Solutions
2.2.4 AstraZeneca, Plc Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 AstraZeneca, Plc Recent Developments and Future Plans
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business
2.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Product and Solutions
2.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.4 Celgene Corporation
2.4.1 Celgene Corporation Details
2.4.2 Celgene Corporation Major Business
2.4.3 Celgene Corporation Immuno-oncology Drugs Product and Solutions
2.4.4 Celgene Corporation Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Celgene Corporation Recent Developments and Future Plans
2.5 Eli Lilly and Company
2.5.1 Eli Lilly and Company Details
2.5.2 Eli Lilly and Company Major Business
2.5.3 Eli Lilly and Company Immuno-oncology Drugs Product and Solutions
2.5.4 Eli Lilly and Company Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Eli Lilly and Company Recent Developments and Future Plans
2.6 Merck & Co.
2.6.1 Merck & Co. Details
2.6.2 Merck & Co. Major Business
2.6.3 Merck & Co. Immuno-oncology Drugs Product and Solutions
2.6.4 Merck & Co. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Merck & Co. Recent Developments and Future Plans
2.7 Hoffmann-La Roche AG
2.7.1 Hoffmann-La Roche AG Details
2.7.2 Hoffmann-La Roche AG Major Business
2.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Product and Solutions
2.7.4 Hoffmann-La Roche AG Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Hoffmann-La Roche AG Recent Developments and Future Plans
2.8 Johnson & Johnson
2.8.1 Johnson & Johnson Details
2.8.2 Johnson & Johnson Major Business
2.8.3 Johnson & Johnson Immuno-oncology Drugs Product and Solutions
2.8.4 Johnson & Johnson Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Johnson & Johnson Recent Developments and Future Plans
2.9 Novartis International AG
2.9.1 Novartis International AG Details
2.9.2 Novartis International AG Major Business
2.9.3 Novartis International AG Immuno-oncology Drugs Product and Solutions
2.9.4 Novartis International AG Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Novartis International AG Recent Developments and Future Plans
2.10 AbbVie, Inc.
2.10.1 AbbVie, Inc. Details
2.10.2 AbbVie, Inc. Major Business
2.10.3 AbbVie, Inc. Immuno-oncology Drugs Product and Solutions
2.10.4 AbbVie, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 AbbVie, Inc. Recent Developments and Future Plans
2.11 Pfizer Inc.
2.11.1 Pfizer Inc. Details
2.11.2 Pfizer Inc. Major Business
2.11.3 Pfizer Inc. Immuno-oncology Drugs Product and Solutions
2.11.4 Pfizer Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Pfizer Inc. Recent Developments and Future Plans
2.12 Sanofi S.A.
2.12.1 Sanofi S.A. Details
2.12.2 Sanofi S.A. Major Business
2.12.3 Sanofi S.A. Immuno-oncology Drugs Product and Solutions
2.12.4 Sanofi S.A. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Sanofi S.A. Recent Developments and Future Plans
2.13 EMD Serono, Inc.
2.13.1 EMD Serono, Inc. Details
2.13.2 EMD Serono, Inc. Major Business
2.13.3 EMD Serono, Inc. Immuno-oncology Drugs Product and Solutions
2.13.4 EMD Serono, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 EMD Serono, Inc. Recent Developments and Future Plans
2.14 Gilead Sciences Inc.
2.14.1 Gilead Sciences Inc. Details
2.14.2 Gilead Sciences Inc. Major Business
2.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Product and Solutions
2.14.4 Gilead Sciences Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Gilead Sciences Inc. Recent Developments and Future Plans
2.15 Prometheus Therapeutics & Diagnostics
2.15.1 Prometheus Therapeutics & Diagnostics Details
2.15.2 Prometheus Therapeutics & Diagnostics Major Business
2.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product and Solutions
2.15.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Prometheus Therapeutics & Diagnostics Recent Developments and Future Plans
2.16 Aduro BioTech
2.16.1 Aduro BioTech Details
2.16.2 Aduro BioTech Major Business
2.16.3 Aduro BioTech Immuno-oncology Drugs Product and Solutions
2.16.4 Aduro BioTech Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Aduro BioTech Recent Developments and Future Plans
2.17 Galena Biopharma
2.17.1 Galena Biopharma Details
2.17.2 Galena Biopharma Major Business
2.17.3 Galena Biopharma Immuno-oncology Drugs Product and Solutions
2.17.4 Galena Biopharma Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Galena Biopharma Recent Developments and Future Plans
2.18 Bavarian Nordic
2.18.1 Bavarian Nordic Details
2.18.2 Bavarian Nordic Major Business
2.18.3 Bavarian Nordic Immuno-oncology Drugs Product and Solutions
2.18.4 Bavarian Nordic Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Bavarian Nordic Recent Developments and Future Plans
2.19 Celldex Therapeutics
2.19.1 Celldex Therapeutics Details
2.19.2 Celldex Therapeutics Major Business
2.19.3 Celldex Therapeutics Immuno-oncology Drugs Product and Solutions
2.19.4 Celldex Therapeutics Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Celldex Therapeutics Recent Developments and Future Plans
2.20 ImmunoCellular Therapeutics
2.20.1 ImmunoCellular Therapeutics Details
2.20.2 ImmunoCellular Therapeutics Major Business
2.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Product and Solutions
2.20.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 ImmunoCellular Therapeutics Recent Developments and Future Plans
2.21 Incyte
2.21.1 Incyte Details
2.21.2 Incyte Major Business
2.21.3 Incyte Immuno-oncology Drugs Product and Solutions
2.21.4 Incyte Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.21.5 Incyte Recent Developments and Future Plans
2.22 Dendreon Corporation
2.22.1 Dendreon Corporation Details
2.22.2 Dendreon Corporation Major Business
2.22.3 Dendreon Corporation Immuno-oncology Drugs Product and Solutions
2.22.4 Dendreon Corporation Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.22.5 Dendreon Corporation Recent Developments and Future Plans
2.23 Agilent Technologies Inc.
2.23.1 Agilent Technologies Inc. Details
2.23.2 Agilent Technologies Inc. Major Business
2.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Product and Solutions
2.23.4 Agilent Technologies Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.23.5 Agilent Technologies Inc. Recent Developments and Future Plans
2.24 Agenus Inc.
2.24.1 Agenus Inc. Details
2.24.2 Agenus Inc. Major Business
2.24.3 Agenus Inc. Immuno-oncology Drugs Product and Solutions
2.24.4 Agenus Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.24.5 Agenus Inc. Recent Developments and Future Plans
2.25 Enzo Biochem, Inc.
2.25.1 Enzo Biochem, Inc. Details
2.25.2 Enzo Biochem, Inc. Major Business
2.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Product and Solutions
2.25.4 Enzo Biochem, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.25.5 Enzo Biochem, Inc. Recent Developments and Future Plans
2.26 Lonza Group
2.26.1 Lonza Group Details
2.26.2 Lonza Group Major Business
2.26.3 Lonza Group Immuno-oncology Drugs Product and Solutions
2.26.4 Lonza Group Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.26.5 Lonza Group Recent Developments and Future Plans
2.27 Bio-Rad Laboratories, Inc.
2.27.1 Bio-Rad Laboratories, Inc. Details
2.27.2 Bio-Rad Laboratories, Inc. Major Business
2.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product and Solutions
2.27.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.27.5 Bio-Rad Laboratories, Inc. Recent Developments and Future Plans
2.28 Avantor, Inc.
2.28.1 Avantor, Inc. Details
2.28.2 Avantor, Inc. Major Business
2.28.3 Avantor, Inc. Immuno-oncology Drugs Product and Solutions
2.28.4 Avantor, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.28.5 Avantor, Inc. Recent Developments and Future Plans
2.29 Spring Bank Pharmaceuticals, Inc.
2.29.1 Spring Bank Pharmaceuticals, Inc. Details
2.29.2 Spring Bank Pharmaceuticals, Inc. Major Business
2.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product and Solutions
2.29.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.29.5 Spring Bank Pharmaceuticals, Inc. Recent Developments and Future Plans
2.30 Ferring Pharmaceuticals
2.30.1 Ferring Pharmaceuticals Details
2.30.2 Ferring Pharmaceuticals Major Business
2.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Product and Solutions
2.30.4 Ferring Pharmaceuticals Immuno-oncology Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.30.5 Ferring Pharmaceuticals Recent Developments and Future Plans
3.1 Global Immuno-oncology Drugs Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Immuno-oncology Drugs by Company Revenue
3.2.2 Top 3 Immuno-oncology Drugs Players Market Share in 2022
3.2.3 Top 6 Immuno-oncology Drugs Players Market Share in 2022
3.3 Immuno-oncology Drugs Market: Overall Company Footprint Analysis
3.3.1 Immuno-oncology Drugs Market: Region Footprint
3.3.2 Immuno-oncology Drugs Market: Company Product Type Footprint
3.3.3 Immuno-oncology Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Immuno-oncology Drugs Consumption Value and Market Share by Type (2018-2023)
4.2 Global Immuno-oncology Drugs Market Forecast by Type (2024-2029)
5.1 Global Immuno-oncology Drugs Consumption Value Market Share by Application (2018-2023)
5.2 Global Immuno-oncology Drugs Market Forecast by Application (2024-2029)
6.1 North America Immuno-oncology Drugs Consumption Value by Type (2018-2029)
6.2 North America Immuno-oncology Drugs Consumption Value by Application (2018-2029)
6.3 North America Immuno-oncology Drugs Market Size by Country
6.3.1 North America Immuno-oncology Drugs Consumption Value by Country (2018-2029)
6.3.2 United States Immuno-oncology Drugs Market Size and Forecast (2018-2029)
6.3.3 Canada Immuno-oncology Drugs Market Size and Forecast (2018-2029)
6.3.4 Mexico Immuno-oncology Drugs Market Size and Forecast (2018-2029)
7.1 Europe Immuno-oncology Drugs Consumption Value by Type (2018-2029)
7.2 Europe Immuno-oncology Drugs Consumption Value by Application (2018-2029)
7.3 Europe Immuno-oncology Drugs Market Size by Country
7.3.1 Europe Immuno-oncology Drugs Consumption Value by Country (2018-2029)
7.3.2 Germany Immuno-oncology Drugs Market Size and Forecast (2018-2029)
7.3.3 France Immuno-oncology Drugs Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Immuno-oncology Drugs Market Size and Forecast (2018-2029)
7.3.5 Russia Immuno-oncology Drugs Market Size and Forecast (2018-2029)
7.3.6 Italy Immuno-oncology Drugs Market Size and Forecast (2018-2029)
8.1 Asia-Pacific Immuno-oncology Drugs Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Immuno-oncology Drugs Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Immuno-oncology Drugs Market Size by Region
8.3.1 Asia-Pacific Immuno-oncology Drugs Consumption Value by Region (2018-2029)
8.3.2 China Immuno-oncology Drugs Market Size and Forecast (2018-2029)
8.3.3 Japan Immuno-oncology Drugs Market Size and Forecast (2018-2029)
8.3.4 South Korea Immuno-oncology Drugs Market Size and Forecast (2018-2029)
8.3.5 India Immuno-oncology Drugs Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Immuno-oncology Drugs Market Size and Forecast (2018-2029)
8.3.7 Australia Immuno-oncology Drugs Market Size and Forecast (2018-2029)
9.1 South America Immuno-oncology Drugs Consumption Value by Type (2018-2029)
9.2 South America Immuno-oncology Drugs Consumption Value by Application (2018-2029)
9.3 South America Immuno-oncology Drugs Market Size by Country
9.3.1 South America Immuno-oncology Drugs Consumption Value by Country (2018-2029)
9.3.2 Brazil Immuno-oncology Drugs Market Size and Forecast (2018-2029)
9.3.3 Argentina Immuno-oncology Drugs Market Size and Forecast (2018-2029)
10.1 Middle East & Africa Immuno-oncology Drugs Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Immuno-oncology Drugs Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Immuno-oncology Drugs Market Size by Country
10.3.1 Middle East & Africa Immuno-oncology Drugs Consumption Value by Country (2018-2029)
10.3.2 Turkey Immuno-oncology Drugs Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Immuno-oncology Drugs Market Size and Forecast (2018-2029)
10.3.4 UAE Immuno-oncology Drugs Market Size and Forecast (2018-2029)
11.1 Immuno-oncology Drugs Market Drivers
11.2 Immuno-oncology Drugs Market Restraints
11.3 Immuno-oncology Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12.1 Immuno-oncology Drugs Industry Chain
12.2 Immuno-oncology Drugs Upstream Analysis
12.3 Immuno-oncology Drugs Midstream Analysis
12.4 Immuno-oncology Drugs Downstream Analysis
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Immuno-oncology Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Immuno-oncology Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Immuno-oncology Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Immuno-oncology Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Amgen, Inc Company Information, Head Office, and Major Competitors
Table 6. Amgen, Inc Major Business
Table 7. Amgen, Inc Immuno-oncology Drugs Product and Solutions
Table 8. Amgen, Inc Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Amgen, Inc Recent Developments and Future Plans
Table 10. AstraZeneca, Plc Company Information, Head Office, and Major Competitors
Table 11. AstraZeneca, Plc Major Business
Table 12. AstraZeneca, Plc Immuno-oncology Drugs Product and Solutions
Table 13. AstraZeneca, Plc Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. AstraZeneca, Plc Recent Developments and Future Plans
Table 15. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 16. Bristol-Myers Squibb Major Business
Table 17. Bristol-Myers Squibb Immuno-oncology Drugs Product and Solutions
Table 18. Bristol-Myers Squibb Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Bristol-Myers Squibb Recent Developments and Future Plans
Table 20. Celgene Corporation Company Information, Head Office, and Major Competitors
Table 21. Celgene Corporation Major Business
Table 22. Celgene Corporation Immuno-oncology Drugs Product and Solutions
Table 23. Celgene Corporation Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Celgene Corporation Recent Developments and Future Plans
Table 25. Eli Lilly and Company Company Information, Head Office, and Major Competitors
Table 26. Eli Lilly and Company Major Business
Table 27. Eli Lilly and Company Immuno-oncology Drugs Product and Solutions
Table 28. Eli Lilly and Company Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Eli Lilly and Company Recent Developments and Future Plans
Table 30. Merck & Co. Company Information, Head Office, and Major Competitors
Table 31. Merck & Co. Major Business
Table 32. Merck & Co. Immuno-oncology Drugs Product and Solutions
Table 33. Merck & Co. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Merck & Co. Recent Developments and Future Plans
Table 35. Hoffmann-La Roche AG Company Information, Head Office, and Major Competitors
Table 36. Hoffmann-La Roche AG Major Business
Table 37. Hoffmann-La Roche AG Immuno-oncology Drugs Product and Solutions
Table 38. Hoffmann-La Roche AG Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Hoffmann-La Roche AG Recent Developments and Future Plans
Table 40. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 41. Johnson & Johnson Major Business
Table 42. Johnson & Johnson Immuno-oncology Drugs Product and Solutions
Table 43. Johnson & Johnson Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Johnson & Johnson Recent Developments and Future Plans
Table 45. Novartis International AG Company Information, Head Office, and Major Competitors
Table 46. Novartis International AG Major Business
Table 47. Novartis International AG Immuno-oncology Drugs Product and Solutions
Table 48. Novartis International AG Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Novartis International AG Recent Developments and Future Plans
Table 50. AbbVie, Inc. Company Information, Head Office, and Major Competitors
Table 51. AbbVie, Inc. Major Business
Table 52. AbbVie, Inc. Immuno-oncology Drugs Product and Solutions
Table 53. AbbVie, Inc. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. AbbVie, Inc. Recent Developments and Future Plans
Table 55. Pfizer Inc. Company Information, Head Office, and Major Competitors
Table 56. Pfizer Inc. Major Business
Table 57. Pfizer Inc. Immuno-oncology Drugs Product and Solutions
Table 58. Pfizer Inc. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Pfizer Inc. Recent Developments and Future Plans
Table 60. Sanofi S.A. Company Information, Head Office, and Major Competitors
Table 61. Sanofi S.A. Major Business
Table 62. Sanofi S.A. Immuno-oncology Drugs Product and Solutions
Table 63. Sanofi S.A. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Sanofi S.A. Recent Developments and Future Plans
Table 65. EMD Serono, Inc. Company Information, Head Office, and Major Competitors
Table 66. EMD Serono, Inc. Major Business
Table 67. EMD Serono, Inc. Immuno-oncology Drugs Product and Solutions
Table 68. EMD Serono, Inc. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. EMD Serono, Inc. Recent Developments and Future Plans
Table 70. Gilead Sciences Inc. Company Information, Head Office, and Major Competitors
Table 71. Gilead Sciences Inc. Major Business
Table 72. Gilead Sciences Inc. Immuno-oncology Drugs Product and Solutions
Table 73. Gilead Sciences Inc. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Gilead Sciences Inc. Recent Developments and Future Plans
Table 75. Prometheus Therapeutics & Diagnostics Company Information, Head Office, and Major Competitors
Table 76. Prometheus Therapeutics & Diagnostics Major Business
Table 77. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product and Solutions
Table 78. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Prometheus Therapeutics & Diagnostics Recent Developments and Future Plans
Table 80. Aduro BioTech Company Information, Head Office, and Major Competitors
Table 81. Aduro BioTech Major Business
Table 82. Aduro BioTech Immuno-oncology Drugs Product and Solutions
Table 83. Aduro BioTech Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Aduro BioTech Recent Developments and Future Plans
Table 85. Galena Biopharma Company Information, Head Office, and Major Competitors
Table 86. Galena Biopharma Major Business
Table 87. Galena Biopharma Immuno-oncology Drugs Product and Solutions
Table 88. Galena Biopharma Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Galena Biopharma Recent Developments and Future Plans
Table 90. Bavarian Nordic Company Information, Head Office, and Major Competitors
Table 91. Bavarian Nordic Major Business
Table 92. Bavarian Nordic Immuno-oncology Drugs Product and Solutions
Table 93. Bavarian Nordic Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Bavarian Nordic Recent Developments and Future Plans
Table 95. Celldex Therapeutics Company Information, Head Office, and Major Competitors
Table 96. Celldex Therapeutics Major Business
Table 97. Celldex Therapeutics Immuno-oncology Drugs Product and Solutions
Table 98. Celldex Therapeutics Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 99. Celldex Therapeutics Recent Developments and Future Plans
Table 100. ImmunoCellular Therapeutics Company Information, Head Office, and Major Competitors
Table 101. ImmunoCellular Therapeutics Major Business
Table 102. ImmunoCellular Therapeutics Immuno-oncology Drugs Product and Solutions
Table 103. ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 104. ImmunoCellular Therapeutics Recent Developments and Future Plans
Table 105. Incyte Company Information, Head Office, and Major Competitors
Table 106. Incyte Major Business
Table 107. Incyte Immuno-oncology Drugs Product and Solutions
Table 108. Incyte Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 109. Incyte Recent Developments and Future Plans
Table 110. Dendreon Corporation Company Information, Head Office, and Major Competitors
Table 111. Dendreon Corporation Major Business
Table 112. Dendreon Corporation Immuno-oncology Drugs Product and Solutions
Table 113. Dendreon Corporation Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 114. Dendreon Corporation Recent Developments and Future Plans
Table 115. Agilent Technologies Inc. Company Information, Head Office, and Major Competitors
Table 116. Agilent Technologies Inc. Major Business
Table 117. Agilent Technologies Inc. Immuno-oncology Drugs Product and Solutions
Table 118. Agilent Technologies Inc. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Agilent Technologies Inc. Recent Developments and Future Plans
Table 120. Agenus Inc. Company Information, Head Office, and Major Competitors
Table 121. Agenus Inc. Major Business
Table 122. Agenus Inc. Immuno-oncology Drugs Product and Solutions
Table 123. Agenus Inc. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 124. Agenus Inc. Recent Developments and Future Plans
Table 125. Enzo Biochem, Inc. Company Information, Head Office, and Major Competitors
Table 126. Enzo Biochem, Inc. Major Business
Table 127. Enzo Biochem, Inc. Immuno-oncology Drugs Product and Solutions
Table 128. Enzo Biochem, Inc. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 129. Enzo Biochem, Inc. Recent Developments and Future Plans
Table 130. Lonza Group Company Information, Head Office, and Major Competitors
Table 131. Lonza Group Major Business
Table 132. Lonza Group Immuno-oncology Drugs Product and Solutions
Table 133. Lonza Group Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 134. Lonza Group Recent Developments and Future Plans
Table 135. Bio-Rad Laboratories, Inc. Company Information, Head Office, and Major Competitors
Table 136. Bio-Rad Laboratories, Inc. Major Business
Table 137. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product and Solutions
Table 138. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 139. Bio-Rad Laboratories, Inc. Recent Developments and Future Plans
Table 140. Avantor, Inc. Company Information, Head Office, and Major Competitors
Table 141. Avantor, Inc. Major Business
Table 142. Avantor, Inc. Immuno-oncology Drugs Product and Solutions
Table 143. Avantor, Inc. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 144. Avantor, Inc. Recent Developments and Future Plans
Table 145. Spring Bank Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 146. Spring Bank Pharmaceuticals, Inc. Major Business
Table 147. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product and Solutions
Table 148. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 149. Spring Bank Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 150. Ferring Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 151. Ferring Pharmaceuticals Major Business
Table 152. Ferring Pharmaceuticals Immuno-oncology Drugs Product and Solutions
Table 153. Ferring Pharmaceuticals Immuno-oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 154. Ferring Pharmaceuticals Recent Developments and Future Plans
Table 155. Global Immuno-oncology Drugs Revenue (USD Million) by Players (2018-2023)
Table 156. Global Immuno-oncology Drugs Revenue Share by Players (2018-2023)
Table 157. Breakdown of Immuno-oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 158. Market Position of Players in Immuno-oncology Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 159. Head Office of Key Immuno-oncology Drugs Players
Table 160. Immuno-oncology Drugs Market: Company Product Type Footprint
Table 161. Immuno-oncology Drugs Market: Company Product Application Footprint
Table 162. Immuno-oncology Drugs New Market Entrants and Barriers to Market Entry
Table 163. Immuno-oncology Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 164. Global Immuno-oncology Drugs Consumption Value (USD Million) by Type (2018-2023)
Table 165. Global Immuno-oncology Drugs Consumption Value Share by Type (2018-2023)
Table 166. Global Immuno-oncology Drugs Consumption Value Forecast by Type (2024-2029)
Table 167. Global Immuno-oncology Drugs Consumption Value by Application (2018-2023)
Table 168. Global Immuno-oncology Drugs Consumption Value Forecast by Application (2024-2029)
Table 169. North America Immuno-oncology Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 170. North America Immuno-oncology Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 171. North America Immuno-oncology Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 172. North America Immuno-oncology Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 173. North America Immuno-oncology Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 174. North America Immuno-oncology Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 175. Europe Immuno-oncology Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 176. Europe Immuno-oncology Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 177. Europe Immuno-oncology Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 178. Europe Immuno-oncology Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 179. Europe Immuno-oncology Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 180. Europe Immuno-oncology Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 181. Asia-Pacific Immuno-oncology Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 182. Asia-Pacific Immuno-oncology Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 183. Asia-Pacific Immuno-oncology Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 184. Asia-Pacific Immuno-oncology Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 185. Asia-Pacific Immuno-oncology Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 186. Asia-Pacific Immuno-oncology Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 187. South America Immuno-oncology Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 188. South America Immuno-oncology Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 189. South America Immuno-oncology Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 190. South America Immuno-oncology Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 191. South America Immuno-oncology Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 192. South America Immuno-oncology Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 193. Middle East & Africa Immuno-oncology Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 194. Middle East & Africa Immuno-oncology Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 195. Middle East & Africa Immuno-oncology Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 196. Middle East & Africa Immuno-oncology Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 197. Middle East & Africa Immuno-oncology Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 198. Middle East & Africa Immuno-oncology Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 199. Immuno-oncology Drugs Raw Material
Table 200. Key Suppliers of Immuno-oncology Drugs Raw Materials
List of Figures
Figure 1. Immuno-oncology Drugs Picture
Figure 2. Global Immuno-oncology Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Immuno-oncology Drugs Consumption Value Market Share by Type in 2022
Figure 4. Immune Checkpoint Inhibitors
Figure 5. Immune System Modulators
Figure 6. Cancer Vaccines
Figure 7. Oncolytic Virus
Figure 8. Others
Figure 9. Global Immuno-oncology Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 10. Immuno-oncology Drugs Consumption Value Market Share by Application in 2022
Figure 11. Hospitals Picture
Figure 12. Clinics Picture
Figure 13. Ambulatory Surgical Centers Picture
Figure 14. Global Immuno-oncology Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Immuno-oncology Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Immuno-oncology Drugs Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Immuno-oncology Drugs Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Immuno-oncology Drugs Consumption Value Market Share by Region in 2022
Figure 19. North America Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Immuno-oncology Drugs Revenue Share by Players in 2022
Figure 25. Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Immuno-oncology Drugs Market Share in 2022
Figure 27. Global Top 6 Players Immuno-oncology Drugs Market Share in 2022
Figure 28. Global Immuno-oncology Drugs Consumption Value Share by Type (2018-2023)
Figure 29. Global Immuno-oncology Drugs Market Share Forecast by Type (2024-2029)
Figure 30. Global Immuno-oncology Drugs Consumption Value Share by Application (2018-2023)
Figure 31. Global Immuno-oncology Drugs Market Share Forecast by Application (2024-2029)
Figure 32. North America Immuno-oncology Drugs Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Immuno-oncology Drugs Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Immuno-oncology Drugs Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Immuno-oncology Drugs Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Immuno-oncology Drugs Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Immuno-oncology Drugs Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 42. France Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Immuno-oncology Drugs Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Immuno-oncology Drugs Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Immuno-oncology Drugs Consumption Value Market Share by Region (2018-2029)
Figure 49. China Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 52. India Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Immuno-oncology Drugs Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Immuno-oncology Drugs Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Immuno-oncology Drugs Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Immuno-oncology Drugs Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Immuno-oncology Drugs Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Immuno-oncology Drugs Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Immuno-oncology Drugs Consumption Value (2018-2029) & (USD Million)
Figure 66. Immuno-oncology Drugs Market Drivers
Figure 67. Immuno-oncology Drugs Market Restraints
Figure 68. Immuno-oncology Drugs Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Immuno-oncology Drugs in 2022
Figure 71. Manufacturing Process Analysis of Immuno-oncology Drugs
Figure 72. Immuno-oncology Drugs Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Amgen, Inc AstraZeneca, Plc Bristol-Myers Squibb Celgene Corporation Eli Lilly and Company Merck & Co. Hoffmann-La Roche AG Johnson & Johnson Novartis International AG AbbVie, Inc. Pfizer Inc. Sanofi S.A. EMD Serono, Inc. Gilead Sciences Inc. Prometheus Therapeutics & Diagnostics Aduro BioTech Galena Biopharma Bavarian Nordic Celldex Therapeutics ImmunoCellular Therapeutics Incyte Dendreon Corporation Agilent Technologies Inc. Agenus Inc. Enzo Biochem, Inc. Lonza Group Bio-Rad Laboratories, Inc. Avantor, Inc. Spring Bank Pharmaceuticals, Inc. Ferring Pharmaceuticals
Related Reports
08 Sep 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
